US 11,834,427 B2
Griseofulvin compound
Keiji Saito, Atsugi (JP); Katsuyoshi Nakajima, Shinagawa-ku (JP); Toru Taniguchi, Bunkyo-ku (JP); Osamu Iwamoto, Yokohama (JP); Satoshi Shibuya, Kawasaki (JP); Yasuyuki Ogawa, Yokosuka (JP); Kazumasa Aoki, Koto-ku (JP); Nobuya Kurikawa, Shinagawa-ku (JP); Shinji Tanaka, Edogawa-ku (JP); Momoko Ogitani, Ota-ku (JP); Eriko Kioi, Yokohama (JP); Kaori Ito, Koto-ku (JP); Natsumi Nishihama, Yokohama (JP); Tsuyoshi Mikkaichi, Saitama (JP); and Wataru Saitoh, Edogawa-ku (JP)
Assigned to Daiichi Sankyo Company, Limited, Tokyo (JP)
Filed by Daiichi Sankyo Company, Limited, Tokyo (JP)
Filed on Oct. 13, 2022, as Appl. No. 18/046,270.
Application 18/046,270 is a continuation of application No. 17/212,373, filed on Mar. 25, 2021, granted, now 11,472,784, issued on Oct. 18, 2022.
Application 17/212,373 is a continuation of application No. 16/844,621, filed on Apr. 9, 2020, granted, now 10,975,052, issued on Apr. 13, 2021.
Application 16/844,621 is a continuation of application No. 16/561,459, filed on Sep. 5, 2019, granted, now 10,654,821, issued on May 19, 2020.
Application 16/561,459 is a continuation of application No. 16/088,696, granted, now 10,570,109, issued on Feb. 25, 2020, previously published as PCT/JP2017/012777, filed on Mar. 29, 2017.
Claims priority of application No. 2016-067076 (JP), filed on Mar. 30, 2016.
Prior Publication US 2023/0136988 A1, May 4, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 307/94 (2006.01); C07D 405/04 (2006.01); C07D 405/10 (2006.01); C07D 407/12 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); A61K 31/343 (2006.01); A61K 31/4155 (2006.01); A61K 31/4245 (2006.01); C07D 413/10 (2006.01)
CPC C07D 307/94 (2013.01) [A61K 31/343 (2013.01); A61K 31/4155 (2013.01); A61K 31/4245 (2013.01); C07D 405/04 (2013.01); C07D 405/10 (2013.01); C07D 407/12 (2013.01); C07D 413/04 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01)] 14 Claims
 
1. A solid oral dosage form comprising a compound of general formula (1) or a pharmacologically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein the symbols in the formula are defined below:
R1: a C1-C6 alkyl group or a hydroxyC1-C6 alkyl group,
R2: a C1-C6 alkyl group,
A: a 5-membered aromatic heterocycle having bonds and having 1-4 atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or an oxygen atom, and
R3: if A is a 5-membered aromatic heterocycle having bonds and having 1-4 atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, then R3 is a C1-C6 alkyl group, a hydroxyC1-C6 alkyl group or a C1-C6 alkoxyC1-C6 alkyl group; and if A is an oxygen atom, then R3 is a hydroxyC1-C6 alkyl group or a C1-C6 alkoxyC1-C6 alkyl group.